ENCAPSULATING PERITONEAL SCLEROSIS: PREVENTION AND TREATMENT
Tsuchiya General Hospital, Hiroshima, Japan Correspondence to: H. Kawanishi, Tsuchiya General Hospital, 3-30 Nakajima-cho, Naka-ku, Hiroshima 730-8655 Japan. h-kawanishi{at}tuschiya-hp.jp Since the first peritoneal dialysis (PD) patients with encapsulating peritoneal sclerosis (EPS) were reported in...
Gespeichert in:
| Veröffentlicht in: | Peritoneal dialysis international 2007-06, Vol.27 (Supplement_2), p.S289-292 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 292 |
|---|---|
| container_issue | Supplement_2 |
| container_start_page | S289 |
| container_title | Peritoneal dialysis international |
| container_volume | 27 |
| creator | Kawanishi, Hideki Moriishi, Misaki |
| description | Tsuchiya General Hospital, Hiroshima, Japan
Correspondence to: H. Kawanishi, Tsuchiya General Hospital, 3-30 Nakajima-cho,
Naka-ku, Hiroshima 730-8655 Japan.
h-kawanishi{at}tuschiya-hp.jp
Since the first peritoneal dialysis (PD) patients with encapsulating
peritoneal sclerosis (EPS) were reported in 1980, EPS has been considered
primarily a fatal complication. The incidence of EPS in PD patients has been
reported to be 2.5%, with a negative effect of increasing PD duration (which
also augments mortality). Because EPS occurs after withdrawal from PD in more
than half of all cases, strict monitoring is necessary when a long-term PD
patient is withdrawn from PD. Maintaining patients on standard PD with
conventional solutions for more than 8 years is associated with a substantial
risk of EPS development. Treatment appropriate to the disease stage is most
important in EPS. Basic therapeutic strategies for EPS include the appropriate
use of steroids. If bowel obstruction persists, laparotomy and enterolysis
should be performed to achieve a complete cure. It is now recognized that EPS
need not be a fatal complication of PD.
KEY WORDS: Encapsulating peritoneal sclerosis; EPS; peritoneal deterioration; surgical options. |
| doi_str_mv | 10.1177/089686080702702s49 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70599030</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70599030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-d461356d895516d87ed8bacb9599c18ce7ac3acd455bd7e9f3f6e07f82242b053</originalsourceid><addsrcrecordid>eNpl0MtKw0AUBuBBFK2XF3Ah2eguOtfMjLgJNWogpqWJbofJZKKRpK2ZluLbO6UFF8KBA4fv_IsfgEsEbxHi_A4KGYkICsgh9uOoPAAjxJEIKYH0EIy2INyKE3Dq3BeEBBPIj8EJ4oxFBKMReEjycTwt3rK4TPPnYJrM0nKSJ3EWFOMsmU2KtLgPprPkPcnLdJIHcf4YlLMkLl_94RwcNbpz9mK_z8DbU1KOX8Js8pyO4yw0lMhVWNMIERbVQjKG_OK2FpU2lWRSGiSM5doQbWrKWFVzKxvSRBbyRmBMcQUZOQM3u9zlsPheW7dSfeuM7To9t4u1Uxz6JEigh3gHzbBwbrCNWg5tr4cfhaDadqb-d-afrvbp66q39d_LviQPrvdAO6O7ZtBz07o_JyXFjHLv0M59th-fm3awyvW663wsVpvNBnNVrJfLzvZ2vlJYFVhI8gsSeH_F</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70599030</pqid></control><display><type>article</type><title>ENCAPSULATING PERITONEAL SCLEROSIS: PREVENTION AND TREATMENT</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Kawanishi, Hideki ; Moriishi, Misaki</creator><creatorcontrib>Kawanishi, Hideki ; Moriishi, Misaki</creatorcontrib><description>Tsuchiya General Hospital, Hiroshima, Japan
Correspondence to: H. Kawanishi, Tsuchiya General Hospital, 3-30 Nakajima-cho,
Naka-ku, Hiroshima 730-8655 Japan.
h-kawanishi{at}tuschiya-hp.jp
Since the first peritoneal dialysis (PD) patients with encapsulating
peritoneal sclerosis (EPS) were reported in 1980, EPS has been considered
primarily a fatal complication. The incidence of EPS in PD patients has been
reported to be 2.5%, with a negative effect of increasing PD duration (which
also augments mortality). Because EPS occurs after withdrawal from PD in more
than half of all cases, strict monitoring is necessary when a long-term PD
patient is withdrawn from PD. Maintaining patients on standard PD with
conventional solutions for more than 8 years is associated with a substantial
risk of EPS development. Treatment appropriate to the disease stage is most
important in EPS. Basic therapeutic strategies for EPS include the appropriate
use of steroids. If bowel obstruction persists, laparotomy and enterolysis
should be performed to achieve a complete cure. It is now recognized that EPS
need not be a fatal complication of PD.
KEY WORDS: Encapsulating peritoneal sclerosis; EPS; peritoneal deterioration; surgical options.</description><identifier>ISSN: 0896-8608</identifier><identifier>EISSN: 1718-4304</identifier><identifier>DOI: 10.1177/089686080702702s49</identifier><identifier>PMID: 17556321</identifier><language>eng</language><publisher>Milton, ON: Multimed</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Combined Modality Therapy ; Emergency and intensive care: renal failure. Dialysis management ; Humans ; Incidence ; Intensive care medicine ; Kidney Failure, Chronic - therapy ; Medical sciences ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Peritoneal Dialysis - adverse effects ; Peritoneal Diseases - epidemiology ; Peritoneal Diseases - etiology ; Peritoneal Diseases - physiopathology ; Peritoneal Diseases - prevention & control ; Renal failure ; Risk Factors ; Sclerosis ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system</subject><ispartof>Peritoneal dialysis international, 2007-06, Vol.27 (Supplement_2), p.S289-292</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-d461356d895516d87ed8bacb9599c18ce7ac3acd455bd7e9f3f6e07f82242b053</citedby><cites>FETCH-LOGICAL-c439t-d461356d895516d87ed8bacb9599c18ce7ac3acd455bd7e9f3f6e07f82242b053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>310,311,315,781,785,790,791,23935,23936,25145,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19942547$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17556321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kawanishi, Hideki</creatorcontrib><creatorcontrib>Moriishi, Misaki</creatorcontrib><title>ENCAPSULATING PERITONEAL SCLEROSIS: PREVENTION AND TREATMENT</title><title>Peritoneal dialysis international</title><addtitle>Perit Dial Int</addtitle><description>Tsuchiya General Hospital, Hiroshima, Japan
Correspondence to: H. Kawanishi, Tsuchiya General Hospital, 3-30 Nakajima-cho,
Naka-ku, Hiroshima 730-8655 Japan.
h-kawanishi{at}tuschiya-hp.jp
Since the first peritoneal dialysis (PD) patients with encapsulating
peritoneal sclerosis (EPS) were reported in 1980, EPS has been considered
primarily a fatal complication. The incidence of EPS in PD patients has been
reported to be 2.5%, with a negative effect of increasing PD duration (which
also augments mortality). Because EPS occurs after withdrawal from PD in more
than half of all cases, strict monitoring is necessary when a long-term PD
patient is withdrawn from PD. Maintaining patients on standard PD with
conventional solutions for more than 8 years is associated with a substantial
risk of EPS development. Treatment appropriate to the disease stage is most
important in EPS. Basic therapeutic strategies for EPS include the appropriate
use of steroids. If bowel obstruction persists, laparotomy and enterolysis
should be performed to achieve a complete cure. It is now recognized that EPS
need not be a fatal complication of PD.
KEY WORDS: Encapsulating peritoneal sclerosis; EPS; peritoneal deterioration; surgical options.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Combined Modality Therapy</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Humans</subject><subject>Incidence</subject><subject>Intensive care medicine</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Peritoneal Dialysis - adverse effects</subject><subject>Peritoneal Diseases - epidemiology</subject><subject>Peritoneal Diseases - etiology</subject><subject>Peritoneal Diseases - physiopathology</subject><subject>Peritoneal Diseases - prevention & control</subject><subject>Renal failure</subject><subject>Risk Factors</subject><subject>Sclerosis</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><issn>0896-8608</issn><issn>1718-4304</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpl0MtKw0AUBuBBFK2XF3Ah2eguOtfMjLgJNWogpqWJbofJZKKRpK2ZluLbO6UFF8KBA4fv_IsfgEsEbxHi_A4KGYkICsgh9uOoPAAjxJEIKYH0EIy2INyKE3Dq3BeEBBPIj8EJ4oxFBKMReEjycTwt3rK4TPPnYJrM0nKSJ3EWFOMsmU2KtLgPprPkPcnLdJIHcf4YlLMkLl_94RwcNbpz9mK_z8DbU1KOX8Js8pyO4yw0lMhVWNMIERbVQjKG_OK2FpU2lWRSGiSM5doQbWrKWFVzKxvSRBbyRmBMcQUZOQM3u9zlsPheW7dSfeuM7To9t4u1Uxz6JEigh3gHzbBwbrCNWg5tr4cfhaDadqb-d-afrvbp66q39d_LviQPrvdAO6O7ZtBz07o_JyXFjHLv0M59th-fm3awyvW663wsVpvNBnNVrJfLzvZ2vlJYFVhI8gsSeH_F</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Kawanishi, Hideki</creator><creator>Moriishi, Misaki</creator><general>Multimed</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070601</creationdate><title>ENCAPSULATING PERITONEAL SCLEROSIS: PREVENTION AND TREATMENT</title><author>Kawanishi, Hideki ; Moriishi, Misaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-d461356d895516d87ed8bacb9599c18ce7ac3acd455bd7e9f3f6e07f82242b053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Combined Modality Therapy</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Humans</topic><topic>Incidence</topic><topic>Intensive care medicine</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Peritoneal Dialysis - adverse effects</topic><topic>Peritoneal Diseases - epidemiology</topic><topic>Peritoneal Diseases - etiology</topic><topic>Peritoneal Diseases - physiopathology</topic><topic>Peritoneal Diseases - prevention & control</topic><topic>Renal failure</topic><topic>Risk Factors</topic><topic>Sclerosis</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawanishi, Hideki</creatorcontrib><creatorcontrib>Moriishi, Misaki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Peritoneal dialysis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawanishi, Hideki</au><au>Moriishi, Misaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ENCAPSULATING PERITONEAL SCLEROSIS: PREVENTION AND TREATMENT</atitle><jtitle>Peritoneal dialysis international</jtitle><addtitle>Perit Dial Int</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>27</volume><issue>Supplement_2</issue><spage>S289</spage><epage>292</epage><pages>S289-292</pages><issn>0896-8608</issn><eissn>1718-4304</eissn><abstract>Tsuchiya General Hospital, Hiroshima, Japan
Correspondence to: H. Kawanishi, Tsuchiya General Hospital, 3-30 Nakajima-cho,
Naka-ku, Hiroshima 730-8655 Japan.
h-kawanishi{at}tuschiya-hp.jp
Since the first peritoneal dialysis (PD) patients with encapsulating
peritoneal sclerosis (EPS) were reported in 1980, EPS has been considered
primarily a fatal complication. The incidence of EPS in PD patients has been
reported to be 2.5%, with a negative effect of increasing PD duration (which
also augments mortality). Because EPS occurs after withdrawal from PD in more
than half of all cases, strict monitoring is necessary when a long-term PD
patient is withdrawn from PD. Maintaining patients on standard PD with
conventional solutions for more than 8 years is associated with a substantial
risk of EPS development. Treatment appropriate to the disease stage is most
important in EPS. Basic therapeutic strategies for EPS include the appropriate
use of steroids. If bowel obstruction persists, laparotomy and enterolysis
should be performed to achieve a complete cure. It is now recognized that EPS
need not be a fatal complication of PD.
KEY WORDS: Encapsulating peritoneal sclerosis; EPS; peritoneal deterioration; surgical options.</abstract><cop>Milton, ON</cop><pub>Multimed</pub><pmid>17556321</pmid><doi>10.1177/089686080702702s49</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0896-8608 |
| ispartof | Peritoneal dialysis international, 2007-06, Vol.27 (Supplement_2), p.S289-292 |
| issn | 0896-8608 1718-4304 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70599030 |
| source | Access via SAGE; MEDLINE |
| subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Combined Modality Therapy Emergency and intensive care: renal failure. Dialysis management Humans Incidence Intensive care medicine Kidney Failure, Chronic - therapy Medical sciences Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Peritoneal Dialysis - adverse effects Peritoneal Diseases - epidemiology Peritoneal Diseases - etiology Peritoneal Diseases - physiopathology Peritoneal Diseases - prevention & control Renal failure Risk Factors Sclerosis Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system |
| title | ENCAPSULATING PERITONEAL SCLEROSIS: PREVENTION AND TREATMENT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T00%3A23%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ENCAPSULATING%20PERITONEAL%20SCLEROSIS:%20PREVENTION%20AND%20TREATMENT&rft.jtitle=Peritoneal%20dialysis%20international&rft.au=Kawanishi,%20Hideki&rft.date=2007-06-01&rft.volume=27&rft.issue=Supplement_2&rft.spage=S289&rft.epage=292&rft.pages=S289-292&rft.issn=0896-8608&rft.eissn=1718-4304&rft_id=info:doi/10.1177/089686080702702s49&rft_dat=%3Cproquest_cross%3E70599030%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70599030&rft_id=info:pmid/17556321&rfr_iscdi=true |